John Wiley & Sons Inc
10 nominees · 3 ballot items.
Election of 10 director nominees; ratification of PwC as independent public accounting firm for FY2026; advisory vote on named executive officer compensation.
Follow how the vote landed and what changed on John Wiley & Sons Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Election of 10 Director Nominees
ManagementBoard: FORElection of ten directors to Wiley's Board (three Class A elected by Class A stock and seven Class B elected by Class B stock) for a one-year term.
- 2
Ratification of appointment of independent public accounting firm
ManagementBoard: FORRatify PricewaterhouseCoopers LLP as the Company’s independent public accounting firm for the fiscal year ending April 30, 2026.
- 3
Non-Binding Advisory Vote of Named Executive Officer Compensation
ManagementBoard: FORAdvisory, non-binding vote on the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.
Nominees on the ballot10
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.7% | 4,422,384 | $168M |
| 2 | Neuberger Berman Group LLC | 5.9% | 3,017,098 | $115M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9% | 2,501,979 | $95M |
| 4 | SCHRODER INVESTMENT MANAGEMENT GROUP | 4.7% | 2,381,895 | $91M |
| 5 | STATE STREET CORP | 4.3% | 2,175,966 | $83M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,719,532 | $66M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 3.4% | 1,706,421 | $65M |
| 8 | BANK OF MONTREAL /CAN/ | 3.1% | 1,586,963 | $60M |
| 9 | BlackRock, Inc. | 2.4% | 1,202,522 | $46M |
| 10 | BROWN ADVISORY INC | 2.3% | 1,190,951 | $45M |
Other Consumer Cyclical sector meetings6
Upcoming shareholder meetings at John Wiley & Sons Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the John Wiley & Sons Inc 2025 annual meeting?
- John Wiley & Sons Inc (WLY) holds its 2025 annual shareholder meeting on Thursday, September 25, 2025.
- What is the record date for the John Wiley & Sons Inc 2025 meeting?
- The record date for the John Wiley & Sons Inc 2025 meeting is Thursday, July 31, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for John Wiley & Sons Inc's 2025 meeting?
- The board is presenting 10 director nominees at the John Wiley & Sons Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the John Wiley & Sons Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the John Wiley & Sons Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.